Jennifer Rocnik, Ph.D.
“I am excited to be part of an organization with a proven track record of launching innovative companies and developing meaningful therapeutics for patients in need.”
Jennifer Rocnik joined TRV in 2022 as an Entrepreneur-in-Residence to help create new companies with a focus on Oncology. Jenn is excited to be part of an organization with a proven track record of launching innovative companies developing meaningful therapeutics for patients in need.
Jenn has more than fifteen years of drug discovery experience in both Biotech and Pharma where she has led multiple research programs from target identification to clinical candidate nomination. Prior to joining TRV, Jenn was Vice President of Discovery Biology at Constellation Pharmaceuticals and was responsible for overseeing the identification of new targets for the research portfolio and leading all in vitro and in vivo biology efforts for the company's drug discovery programs. Prior to Constellation, Jenn held roles at Nimbus Therapeutics where she was Head of Biology and responsible for leading programs in Oncology and Immuno-Oncology, the Oncology division of Sanofi where she led cross-functional global drug discovery project teams and Novartis Institutes for Biomedical Research where she led a number of Oncology target validation and early drug discovery programs.
Jenn received her Ph.D. in Molecular Medicine from Boston University School of Medicine and completed her postdoctoral fellowship at Brigham and Women's Hospital.
Outside of work Jenn can usually be found at an ice rink either playing, watching, or coaching hockey or else snowboarding or hiking with her daughter and son.